The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Cg Oncology Inc (NASDAQ: CGON) closed at $43.05 in the last session, up 0.47% from day before closing price of $42.85. In other words, the price has increased by $0.47 from its previous closing price. On the day, 1.23 million shares were traded. CGON stock price reached its highest trading level at $45.03 during the session, while it also had its lowest trading level at $42.805.
Ratios:
We take a closer look at CGON’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 22.15 and its Current Ratio is at 22.15. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Guggenheim on October 08, 2025, initiated with a Buy rating and assigned the stock a target price of $90.
On August 19, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $55.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 13 ’25 when POST LEONARD E sold 1,000 shares for $43.25 per share. The transaction valued at 43,250 led to the insider holds 0 shares of the business.
Mulay James sold 5,903 shares of CGON for $259,673 on Oct 09 ’25. The Director now owns 0 shares after completing the transaction at $43.99 per share. On Oct 09 ’25, another insider, JAMES MULAY, who serves as the Director of the company, bought 6,557 shares for $40.71 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGON now has a Market Capitalization of 3282458368 and an Enterprise Value of 2622400256. For the stock, the TTM Price-to-Sale (P/S) ratio is 5968.11 while its Price-to-Book (P/B) ratio in mrq is 4.90. Its current Enterprise Value per Revenue stands at 4759.347 whereas that against EBITDA is -16.694.
Stock Price History:
The Beta on a monthly basis for CGON is 1.24, which has changed by 0.1656692 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, CGON has reached a high of $45.56, while it has fallen to a 52-week low of $14.80. The 50-Day Moving Average of the stock is 30.32%, while the 200-Day Moving Average is calculated to be 54.24%.
Shares Statistics:
According to the various share statistics, CGON traded on average about 969.89K shares per day over the past 3-months and 1145680 shares per day over the past 10 days. A total of 76.23M shares are outstanding, with a floating share count of 45.56M. Insiders hold about 40.24% of the company’s shares, while institutions hold 77.39% stake in the company. Shares short for CGON as of 1759190400 were 11991344 with a Short Ratio of 12.36, compared to 1756425600 on 10232411. Therefore, it implies a Short% of Shares Outstanding of 11991344 and a Short% of Float of 16.650000000000002.
Earnings Estimates
. The current market rating for Cg Oncology Inc (CGON) reflects the collective analysis of 10.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.44 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$1.77 and -$2.3 for the fiscal current year, implying an average EPS of -$2.07. EPS for the following year is -$2.23, with 10.0 analysts recommending between -$0.9 and -$3.8.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for CGON’s current fiscal year. The highest revenue estimate was $9.5M, while the lowest revenue estimate was $52k, resulting in an average revenue estimate of $1.39M. In the same quarter a year ago, actual revenue was $1.14M
